Why Europe’s Alzheimer’s testing pathway could shift after Fujirebio’s latest CE marking
Alzheimer’s testing needs scale, not just science. Fujirebio’s CE-marked pTau 217 assay pushes blood biomarkers closer to routine care.
What Spear Bio’s new pTau 217 assay reveals about where Alzheimer’s biomarker detection is heading
Spear Bio debuts BD-pTau 217, alpha-synuclein and pS129-a-syn assays at AD/PD 2026. What the claims mean for Alzheimer’s and Parkinson’s research. Read the analysis.
Could Fujirebio’s pTau 217 CSF assay become a new standard in Alzheimer’s research?
Find out how Fujirebio’s new Lumipulse pTau 217 CSF assay could shape the future of Alzheimer’s biomarker research and platform-based diagnostics.